The interim report is set for release at 8:00 a.m. CEST on the same day. During the afternoon briefing, CEO Peter Forsell, CFO Andreas Öhrnberg, and Chief Corporate Affairs Officer Nicole Pehrsson will outline the company's performance. Participants can join the presentation via a dedicated webcast portal or register for the teleconference to receive dial-in credentials.
Implantica Sets August 21 Date for Second Quarter Results
Investors will get a clear look at Implantica’s financial health on August 21 when the Vaduz-based medtech firm publishes its second quarter 2026 report. The company scheduled an English-language webcast and teleconference for 15:00 CEST that day to discuss the findings with stakeholders and market analysts.
Implantica, currently listed on the Nasdaq First North Premier Growth Market in Stockholm, centers its operations on advanced implantable technologies. The company’s primary focus remains its CE-marked RefluxStop device, designed to treat gastroesophageal reflux disease. Beyond this, the firm maintains a pipeline involving eHealth remote monitoring and wireless energy platforms intended to power implants through intact skin.
Comments (0)
No comments yet. Be the first!